COMP <GO>
ILMN vs ELV // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Illumina Inc. (NASDAQ) VS. Elevance Health Inc. (NYSE) • 15-METRIC TALLY: ILMN 7
— ELV 7
■ METRIC PARITY
LAST: $235.99 (-18.64%) • MKT CAP: $43.80B
options-implied-move
—
LAST: $420.07 (-0.46%) • MKT CAP: $91.18B
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ILMN VS. ELV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ILMN | ELV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 66.10% | 89.40% | -23.30 | ELV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.20% | 8.70% | +9.50 | ILMN | /roic <GO> |
| EV/EBITDA & P/E Valuation | 47.5x | 13.8x | +33.70 | ELV | /valuation <GO> |
| Free Cash Flow Yield | 2.13% | 3.48% | -1.35 | ELV | /fcf-yield <GO> |
| Operating Margin | 18.60% | 3.60% | +15.00 | ILMN | /operating-margins <GO> |
| Net Profit Margin | 19.60% | 2.80% | +16.80 | ILMN | /net-margins <GO> |
| Revenue Growth (YoY) | -0.70% | 12.50% | -13.20 | ELV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 1.68% | -1.68 | ELV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.52 | 3.17 | +6.35 | ILMN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | ILMN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.1 | 52.0 | +5.10 | ILMN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.16 | 1.07 | +0.09 | ILMN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 47.9x | 13.5x | +34.40 | ELV | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $43.80B | $91.18B | -$47.38B | ELV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ILMN REV | ELV REV | ILMN GROSS % | ELV GROSS % | ILMN FCF | ELV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.34B | $199.13B | 66.1% | 89.4% | $931.0M | $3.17B |
| FY 2024 | $4.37B | $177.01B | 65.4% | 88.8% | $709.0M | $4.55B |
| FY 2023 | $4.50B | $171.34B | — | — | $275.3M | $350.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ILMN // BETA 1.16
ELV // BETA 1.07